Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer-Reference-Cited by-同舟云学术

Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer

Published:2017-01-12 Issue:4 Volume:116 Page:464-471
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Ioka T,Komatsu Y,Mizuno N,Tsuji A,Ohkawa S,Tanaka M,Iguchi H,Ishiguro A,Kitano M,Satoh T,Yamaguchi T,Takeda K,Kida M,Eguchi K,Ito T,Munakata M,Itoi T,Furuse J,Hamada C,Sakata Y

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2016436.pdf

Reference22 articles.

1. Burris HA, Moore MI, Anderson J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 15: 2403–2413.

2. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreas cancer. N Engl J Med 364: 1817–1825.

3. Gill S, Ko YJ, Cripps M, Beaudoin A, Dhesy-Thind SK, Zulfiqar M, Zalewski P, Do T, Cano PO, Lam W, Dowden SD, Grassin H, Stewart J, Moore MJ (2016) PANCREOX: a randomized Phase III study of 5-fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol 34: 3914–3920.

4. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH, Lee JS (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non–small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24: 2237–2244.

5. Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, Paré L, Culverhouse R, McLeod HL, Baiget M (2008) Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res 14: 1788–1796.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic Review of Single-Agent vs. Multi-Agent Chemotherapy for Advanced Pancreatic Adenocarcinoma in Elderly vs. Younger Patients;Cancers;2023-04-13

2. Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials;PLOS ONE;2023-03-02

3. Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review;Cancer Treatment Reviews;2023-02

4. Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer;BMJ Open;2022-05

5. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3);European Journal of Cancer;2021-11